脓毒症相关肾损伤临床预后的影响因素研究进展

doi:10.3969/j.issn.1004-583X.2026.01.014

摘要/Abstract

摘要：

脓毒症相关肾损伤是脓毒症常见并发症,其可延长脓毒症患者住院时间,增加肾脏替代治疗风险及死亡风险。脓毒症相关肾损伤发生后,肾功能的恢复与否与其预后显著相关。临床治疗因素如液体复苏、升压药物、肾脏替代治疗选择时机等对肾功能恢复起着重要因素。优化临床干预治疗因素,制定个性化的治疗方案,减少相关并发症的发生,有利于促进肾功能恢复。该文将结合脓毒症相关肾损伤发生的病理生理机制,对影响其肾功能恢复的主要临床治疗因素的相关研究进行综述。

关键词: 脓毒症, 脓毒症相关肾损伤, 肾功能恢复, 临床因素

中图分类号:

R631

肖慧敏. 脓毒症相关肾损伤临床预后的影响因素研究进展[J]. 临床荟萃, 2026, 41(1): 78-83.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.01.014

https://www.lchc.cn/CN/Y2026/V41/I1/78

参考文献 49

[1]	Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11):1181-1247. doi: 10.1007/s00134-021-06506-y.
[2]	Zarbock A, Nadim MK, Pickkers P, et al. Sepsis-associated acute kidney injury: Consensus report of the 28th Acute Disease Quality Initiative workgroup[J]. Nat Rev Nephrol, 2023, 19(6):401-417. doi: 10.1038/s41581-023-00683-3.
[3]	Liu J, Xie H, Ye Z, et al. Rates, predictors, and mortality of sepsis-associated acute kidney injury: A systematic review and meta-analysis[J]. BMC Nephrol, 2020, 21(1):318. doi: 10.1186/s12882-020-01974-8.
[4]	Kellum JA, Chawla LS, Keener C, et al. The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock[J]. Am J Respir Crit Care Med, 2016, 193(3):281-287. doi: 10.1164/rccm.201505-0995OC.
[5]	Bouchard J, Acharya A, Cerda J, et al. A prospective international multicenter study of AKI in the intensive care unit[J]. Clin J Am Soc Nephrol, 2015, 10(8):1324-1331. doi: 10.2215/CJN.04360514.
[6]	Mehta RL, Bouchard J, Soroko SB, et al. Sepsis as a cause and consequence of acute kidney injury: Program to improve care in acute renal disease[J]. Intensive Care Med, 2011, 37(2):241-248. doi: 10.1007/s00134-010-2089-9.
[7]	Kellum JA, Sileanu FE, Murugan R, et al. Classifying AKI by urine output versus serum creatinine level[J]. J Am Soc Nephrol, 2015, 26(9):2231-2238. doi: 10.1681/ASN.2014070724.
[8]	Sood MM, Shafer LA, Ho J, et al. Early reversible acute kidney injury is associated with improved survival in septic shock[J]. J Crit Care, 2014, 29(5):711-717. doi: 10.1016/j.jcrc.2014.04.003.
[9]	Peerapornratana S, Manrique-Caballero CL, Gómez H, et al. Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment[J]. Kidney Int, 2019, 96(5):1083-1099. doi: 10.1016/j.kint.2019.05.026.
[10]	Murugan R, Karajala-Subramanyam V, Lee M, et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival[J]. Kidney Int, 2010, 77(6):527-535. doi: 10.1038/ki.2009.502.
[11]	Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure[J]. Kidney Int, 2006, 69(11):1996-2002. doi: 10.1038/sj.ki.5000440.
[12]	Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury[J]. Shock, 2014, 41(1):3-11. doi: 10.1097/SHK.0000000000000052.
[13]	Dellepiane S, Marengo M, Cantaluppi V. Detrimental cross-talk between sepsis and acute kidney injury: New pathogenic mechanisms, early biomarkers and targeted therapies[J]. Crit Care, 2016, 20(1):61. doi: 10.1186/s13054-016-1219-3.
[14]	Prowle JR, Bellomo R. Sepsis-associated acute kidney injury: Macrohemodynamic and microhemodynamic alterations in the renal circulation[J]. Semin Nephrol, 2015, 35(1):64-74. doi: 10.1016/j.semnephrol.2015.01.007.
[15]	Verma SK, Molitoris BA. Renal endothelial injury and microvascular dysfunction in acute kidney injury[J]. Semin Nephrol, 2015, 35(1):96-107. doi: 10.1016/j.semnephrol.2015.01.010.
[16]	Darmon M, Timsit JF, Francais A, et al. Association between hypernatraemia acquired in the ICU and mortality: A cohort study[J]. Nephrol Dial Transplant, 2010, 25(8):2510-2515. doi: 10.1093/ndt/gfq067.
[17]	Li Z, Lu S, Li X. The role of metabolic reprogramming in tubular epithelial cells during the progression of acute kidney injury[J]. Cell Mol Life Sci, 2021, 78(15):5731-5741. doi: 10.1007/s00018-021-03892-w.
[18]	Gómez H, Kellum JA, Ronco C. Metabolic reprogramming and tolerance during sepsis-induced AKI[J]. Nat Rev Nephrol, 2017, 13(3):143-51. doi: 10.1038/nrneph.2016.186.
[19]	Zhu Z, Hu J, Chen Z, et al. Transition of acute kidney injury to chronic kidney disease: Role of metabolic reprogramming[J]. Metabolism, 2022, 131:155194. doi: 10.1016/j.metabol.2022.155194.
[20]	van Mourik N, Geerts BF, Binnekade JM, et al. A higher fluid balance in the days after septic shock reversal is associated with increased mortality: An observational cohort study[J]. Crit Care Explor, 2020, 2(10):e0219. doi: 10.1097/CCE.0000000000000219.
[21]	Chua HR, Wong WK, Ong VH, et al. Extended mortality and chronic kidney disease after septic acute kidney injury[J]. J Intensive Care Med, 2020, 35(6):527-535. doi: 10.1177/0885066618764617.
[22]	Macdonald SPJ, Keijzers G, Taylor DM, et al. Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH): A pilot randomised controlled trial[J]. Intensive Care Med, 2018, 44(12):2070-2078. doi: 10.1007/s00134-018-5433-0.
[23]	Shahnoor H, Divi R, Palle LRA, et al. The effects of restrictive fluid resuscitation on the clinical outcomes in patients with sepsis or septic shock: A meta-analysis of randomized- controlled trials[J]. Cureus, 2023, 15(9):e45620. doi: 10.7759/cureus.45620.
[24]	Kellum JA, Mythen MG, Shaw AD. The 12th consensus conference of the acute dialysis quality initiative (ADQI XII)[J]. Br J Anaesth, 2014, 113(5):729-731. doi: 10.1093/bja/aeu140.
[25]	Kellum DJA, Chawla DLS, Keener MC, et al. The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock[J]. Am J Respir Crit Care Med, 2016, 193(3):281-287. doi: 10.1164/rccm.201505-0995OC.
[26]	Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically Ill adults[J]. N Engl J Med, 2018, 378(9):829-839. doi: 10.1056/NEJMoa1711584.
[27]	Zampieri FG, Cavalcanti AB, Di Tanna GL, et al. Balanced crystalloids versus saline for critically ill patients (BEST-Living): A systematic review and individual patient data meta-analysis[J]. Lancet Respir Med, 2024, 12(3):237-246. doi: 10.1016/S2213-2600(23)00417-4.
[28]	Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock[J]. N Engl J Med, 2014, 370(15):1412-1421. doi: 10.1056/NEJMoa1305727.
[29]	Frenette AJ, Bouchard J, Bernier P, et al. Albumin administration is associated with acute kidney injury in cardiac surgery: A propensity score analysis[J]. Crit Care, 2014, 18(6):602. doi: 10.1186/s13054-014-0602-1.
[30]	Skytte Larsson J, Bragadottir G, Redfors B, et al. Renal effects of norepinephrine-induced variations in mean arterial pressure after liver transplantation: A randomized cross-over trial[J]. Acta Anaesthesiol Scand, 2018, 62(9):1229-36. doi: 10.1111/aas.13156.
[31]	Lankadeva YR, Kosaka J, Evans RG, et al. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury[J]. Kidney Int, 2016, 90(1):100-108. doi: 10.1016/j.kint.2016.02.017.
[32]	Al-Husinat L, Alsabbah A, Hmaid AA, et al. Norepinephrine may exacerbate septic acute kidney injury: A narrative review[J]. JCM, 2023, 12(4):1373. doi: 10.3390/jcm12041373.
[33]	Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial[J]. JAMA, 2016, 316(5):509. doi: 10.1001/jama.2016.10485.
[34]	Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock[J]. Intensive Care Med, 2010, 36(1):83-91. doi: 10.1007/s00134-009-1687-x.
[35]	Kalantari K, Rosner MH. Recent advances in the pharmacological management of sepsis-associated acute kidney injury[J]. Expert Rev Clin Pharmacol, 2021, 14(11):1401-1411. doi: 10.1080/17512433.2021.1978287.
[36]	Lankadeva YR, Kosaka J, Evans RG, et al. Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin ii therapy in septic acute kidney injury[J]. Crit Care Med, 2018, 46(1):e41-e48. doi: 10.1097/CCM.0000000000002797.
[37]	Wan L, Langenberg C, Bellomo R, et al. Angiotensin II in experimental hyperdynamic sepsis[J]. Crit Care, 2009, 13(6):R190. doi: 10.1186/cc8185.
[38]	Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II[J]. Crit Care Med, 2018, 46(6):949-957. doi: 10.1097/CCM.0000000000003092.
[39]	Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock[J]. N Engl J Med, 2014, 370(17):1583-1593. doi: 10.1056/NEJMoa1312173.
[40]	Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: A randomized clinical trial[J]. JAMA, 2020, 323(10):938. doi: 10.1001/jama.2020.0930.
[41]	Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN randomized clinical trial[J]. JAMA, 2016, 315(20):2190. doi: 10.1001/jama.2016.5828.
[42]	Fan Y, Chen L, Jiang S, et al. Timely renal replacement therapy linked to better outcome in patients with sepsis-associated acute kidney injury[J]. J Intensive Med, 2022, 2(3):173-182. doi: 10.1016/j.jointm.2022.03.004.
[43]	Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: A prospective randomized double-blind placebo-controlled trial[J]. Crit Care, 2012, 16(1):R14. doi: 10.1186/cc11159.
[44]	Pickkers P, Mehta RL, Murray PT, et al. Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: A randomized clinical trial[J]. JAMA, 2018, 320(19):1998. doi: 10.1001/jama.2018.14283.
[45]	Pickkers P, Angus DC, Arend J, et al. Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury[J]. BMJ Open, 2023, 13(4):e065613. doi: 10.1136/bmjopen-2022-065613.
[46]	Lerolle N, Nochy D, Guérot E, et al. Histopathology of septic shock induced acute kidney injury: Apoptosis and leukocytic infiltration[J]. Intensive Care Med, 2010, 36(3):471-478. doi: 10.1007/s00134-009-1723-x.
[47]	Guo R, Wang Y, Minto AW, et al. Acute renal failure in endotoxemia is dependent on caspase activation[J]. J Am Soc Nephrol, 2004, 15(12):3093-3102. doi: 10.1097/01.ASN.0000145530.73247.F5.
[48]	Eirin A, Li Z, Zhang X, et al. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis[J]. Hypertension, 2012, 60(5):1242-1249. doi: 10.1161/HYPERTENSIONAHA.112.199919.
[49]	De Barcelos IP, Emmanuele V, Hirano M. Advances in primary mitochondrial myopathies[J]. Curr Opin Neurol, 2019, 32(5):715-721. doi: 10.1097/WCO.0000000000000743.

脓毒症相关肾损伤临床预后的影响因素研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

编辑推荐

Metrics

本文评价

[1]	沈健, 庾胜, 顾晓蕾, 夏天, 龚菊. 多重RT-qPCR在脓毒症患者病原体检测中的应用[J]. 临床荟萃, 2025, 40(9): 796-800.
[2]	庄蕙萃, 郭皓, 李贤, 崔东升. 血流感染合并脓毒症患者预后危险因素及其预测价值分析[J]. 临床荟萃, 2025, 40(8): 698-704.
[3]	武媛媛, 孟舰. 代谢重编程在脓毒症相关急性肾损伤中的研究进展[J]. 临床荟萃, 2025, 40(8): 753-757.
[4]	赵浩天, 任贺江, 赵鹤龄. 左西孟旦在脓毒症及脓毒症休克中的应用研究进展[J]. 临床荟萃, 2025, 40(1): 82-85.
[5]	王茜, 尹万红, 邹同娟, 铁馨, 朱俊臣, 陈侣林, 曾学英. 机械通气脓毒症患者肺部超声重力依赖失充气表型与不良预后的相关性[J]. 临床荟萃, 2024, 39(4): 314-319.
[6]	黄赛虎, 龙中洁, 董兴强, 孟祥营, 吴水燕, 柏振江. 血液肿瘤患儿合并脓毒血症的病原学特点及临床特征[J]. 临床荟萃, 2024, 39(1): 38-42.
[7]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[8]	唐爱军, 汪丽韡. 脓毒症患者入院时血小板计数及凝血指标对28天生存状况的预测价值[J]. 临床荟萃, 2023, 38(3): 250-254.
[9]	周利娟, 诸彭伟, 曹梅, 程真梅, 吴峤微, 李勇. 铁蛋白、红细胞参数及血浆D-二聚体与儿童脓毒症的相关性[J]. 临床荟萃, 2023, 38(1): 60-63.
[10]	周彬, 曾词正, 黄宇戈, 钟娩玲, 吴家园. pSOFA评分联合C-反应蛋白、降钙素原在脓毒症患儿预后评估中的作用[J]. 临床荟萃, 2022, 37(7): 616-622.
[11]	张孟媛, 朱勇. 降钙素原清除率及序贯器官衰竭估计评分对脓毒症患者预后的预测价值[J]. 临床荟萃, 2022, 37(3): 225-229.
[12]	肖刘牛, 钟燕霞, 李树生. 体外血液净化技术对脓毒症临床预后及细胞因子影响的Meta分析[J]. 临床荟萃, 2022, 37(1): 5-13.
[13]	侯伟, 张丽君, 张曼, 王亚坤, 贾美轩, 田利远. 外周血白细胞不高的脓毒症患儿84例临床分析[J]. 临床荟萃, 2021, 36(9): 799-802.
[14]	Eamran Hossain, 田亚, 陈源, 张少丹, 张会丰. IPEX综合征并发肠源性脓毒症1例并文献复习[J]. 临床荟萃, 2021, 36(5): 453-457.
[15]	高其庆, 李卓虹, 周浩, 彭劼. 脓毒症相关性血小板减少[J]. 临床荟萃, 2021, 36(10): 946-950.